LECT2, A Novel and Direct Biomarker of Liver Fibrosis in Patients With CHB

LECT2, A Novel and Direct Biomarker of Liver Fibrosis in Patients With CHB

Chronic hepatitis B (CHB) patients with severe liver fibrosis would be more likely to progress to a poorer prognosis. Treatment is considered once the liver fibrosis reaches significant liver fibrosis (≥S2). Leukocyte cell-derived chemotaxin-2 (LECT2) has been shown to contribute to liver fibrosis p...

Full description

Bibliographic Details
Main Authors: Honghai Xu, Xutong Li, Zihao Wu, Linyan Zhao, Jiapei Shen, Jiaying Liu, Jiangfeng Qin, Yuanlong Shen, Jing Ke, Yuanyuan Wei, Jiabin Li, Yufeng Gao
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Molecular Biosciences
Subjects:
LECT2
direct biomarker
diagnosis
liver fibrosis
CHB
Online Access:https://www.frontiersin.org/articles/10.3389/fmolb.2021.749648/full

Internet

https://www.frontiersin.org/articles/10.3389/fmolb.2021.749648/full

Similar Items